Exemestane is a third-generation aromatase inhibitor originally developed by Pharmacia & Upjoin (now a subsidiary of Pfizer). It was first approved in the UK in April 1999 and has been marketed in several countries for clinical use in the treatment of advanced breast cancer in postmenopausal women. Exemestane tablets are an effective and selective treatment for postmenopausal hormone-dependent breast cancer. Exemestane tablets, as third-generation aromatase inhibitors, are with strong selectivity and long-lasting effects. They can also control breast cancer growth by inhibiting aromatase and blocking estrogen production.

According to CRI’s market research, Pharmacia & Upjoin’s exemestane was not introduced into the Chinese market until 2008, when several generic drugs from local Chinese companies were already available in the Chinese market, of which the exemestane tablets from Qilu Pharmaceutical was already marketed in China in 2002. Pharmacia &Upjoin’s exemestane (trade name AROMASIN^®) is extremely competitive in the Chinese market, accounting for more than 90% of China’s exemestane market in 2020 in terms of sales value. Despite the impact of the COVID-19 outbreak on the Chinese healthcare industry in early 2020, the sales value of exemestane in the Chinese market continued to grow in 2020, reaching approximately CNY400 million (USD61.6 million), with a CAGR of 9.2% from 2016 to 2020.

Breast cancer has replaced lung cancer as the number one cancer worldwide due to the rapid growth in the number of new cases in 2020. The increasing breast cancer cases are fundamentally caused by the altering risk factors for breast cancer, such as changing lifestyles and notions of marriage and childbearing due to economic growth, namely a general rise in the age of women having children, a decrease in the average number of births, overweight, obesity and lack of exercise, all contributing to the increase in the incidence of breast cancer. CRI expects that from 2021 to 2025, new cases of breast cancer in China will continue to grow, resulting in increases in both sales volume and value of exemestane in the Chinese market.

Topics Covered:

• Impact of COVID-19 on China’s Exemestane Market
• Development Environment of Exemestane in China
• Sales Volume of Exemestane in China
• Sales Volume and Value of Exemestane in China by Region
• Major Exemestane Manufacturers in China and Their Market Shares
• Sales Price of Exemestane in China
• Prospects of China’s Exemestane Market, 2021-2025

The post Research Report on China’s Exemestane Market, 2021-2025 first appeared on CRI Report.

Depression is the result of a complex interplay of social, psychological and physical factors. People who experience adverse events in their lives are more likely to develop depression. Depression can lead to greater stress and dysfunction, affecting the life of patients and exacerbating their depressive symptoms.

Depression is the fourth leading disease in the world and is expected to become the first leading one by 2030. However, the medical management of depression in China is still under-recognized, with less than 20% of depressed patients at all levels of hospital care and less than 20% of Chinese depressed patients receiving relevant medication. Moreover, the cases of depression and depression-caused suicides are at a younger age (college, and even primary and secondary school students). According to WHO, more than 350 million people worldwide are suffering from depression, with a growth rate of about 18% over the last decade. It is estimated that, by 2021, the number of people suffering from depression in China is about 95 million.

Current treatment for depression is mainly based on antidepressant medication, supplemented by psychotherapy or physical therapy. serotonin-norepinephrine reuptake inhibitors (SNRIs), as one of the used drugs, are antidepressants used to treat major depressive disorder and other psychiatric disorders.

Venlafaxine was the first approved SNRI inhibitor. It was originally developed by Wyeth, a subsidiary of Pfizer, under the trade name Effexor XR^®. The immediate-release form of venlafaxine for the treatment of depression was marketed in the United States in 1994, and later in 1997, the extended-release form of venlafaxine was approved by the FDA. The extended-release form has a smoother onset of action than the immediate-release form and reaches lower peak concentrations, thus causing fewer adverse effects.

According to CRI’s market research, in 1998, the generic drug of venlafaxine from Chengdu Kanghong Pharmaceutical Group, Venlafaxine Capsules (trade name: Bolexin^®) was launched in China, becoming the first domestic venlafaxine product. The original drug, Pfizer’s Effexor XR was not marketed in China until 2001, followed by a number of generic drugs from local Chinese companies. Although Effexor XR was late to enter China’s market, it still holds a major market share. In 2020, Effexor XR accounted for about 50% of the market share in China in terms of sales value.

According to CRI’s market research, in 2020, because of the impact of COVID-19, Chinese healthcare institutions could not function properly, making the sales value of venlafaxine decrease from that of 2019 to approximately CNY294 million (USD45.2 million), with a CAGR of approximately 7.4% from 2016 to 2020. China’s venlafaxine market is expected to see growth from 2021 to 2025 as COVID-19 is under control in China.

CRI expects that the rising stress of Chinese residents’ life brought about by the developing economy, rising urbanization, accelerated pace of work and changing interpersonal relationships, the number of depressed patients in China will continue to grow in the future, and the sales volume and value of antidepressants, including venlafaxine, will increase year by year in the Chinese market.

Topics Covered:

• Impact of COVID-19 on China’s Venlafaxine Market
• Development Environment of Venlafaxine in China
• Sales Volume of Venlafaxine in China
• Sales Volume and Value of Venlafaxine in China by Region
• Major Venlafaxine Manufacturers in China and Their Market Shares
• Sales Price of Venlafaxine in China
• Prospects of China’s Venlafaxine Market, 2021-2025

Global Depression Screening Market Research Report-Forecast to 2023

The post Research Report on China’s Venlafaxine Market, 2021-2025 first appeared on CRI Report.

In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd. LYRICA was launched in China in 2010 and was approved for the treatment of post-herpetic neuralgia. In 2018, it was approved for fibromyalgia indication. Subsequently, some generic drugs of Pregabalin were launched in China one after another.

In 2019, Pregabalin (trade name: Laireike) produced by Chongqing Saiwei Pharmaceutical was approved for the treatment of adult partial epilepsy, adding a new indication for Pregabalin in the Chinese market. By 2020, Pregabalin has been included in China’s Class B medical insurance, and there are three manufactures in the Chinese market, of which Pfizer Ltd is the main manufacture.

CRI expects that with the addition of new companies, the sales volume and market scale of Pregabalin in the Chinese market will continue to expand from 2021 to 2025. According to CRI’s market research, by the first half of 2021, there are more than 20 companies in China that are applying for Pregabalin generic drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. In addition, China has approved the marketing of 3 indications of Pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of indications of Pregabalin in China is likely to increase, and sales value and sales volume will increase in the future.

Topics Covered in Investigation Report on China’s Pregabalin Market 2021-2025

• -The impact of COVID-19 on China’s Pregabalin market
• – Sales value of China’s Pregabalin 2016-2020
• – Competitive landscape of China’s Pregabalin market
• – Prices of Pregabalin in China
• – Prices of Pregabalin in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Pregabalin market
• – Prospect of China’s Pregabalin market from 2021 to 2025

Investigation Report on Chinese Pregabalin Market, 2020-2024

The post Investigation Report on China’s Pregabalin Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of tigecycline in the Chinese market increased year by year at a compound annual growth rate of 43.45% from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of tigecycline in the Chinese market decreased to CNY 885 million in 2020 and the CAGR of tigecycline sales value from 2016 to 2020 is 28.64%.

CRI expects that the sales value of tigecycline in the Chinese market will have a restorative growth from 2016 to 2020 with the relief of COVID-19. According to the latest set of data disclosed by the World Health Organization, 700,000 people worldwide die each year due to “super bacteria” infection, and 230,000 newborns die prematurely because of this. It can be estimated that by 2050, the number of deaths may exceed 10 million. Therefore, the sales value and sales volume of tigecycline against “super bacteria” such as methicillin-resistant Staphylococcus aureus (MRSA) will continue to rise. By the first half of 2021, the new indication for tigecycline in the Chinese market-community and hospital-acquired pneumonia is under review. It can be expected that with the increase in new indications in the future, the sales value and sales volume of tigecycline have room to rise.

Topics Covered:

• -The impact of COVID-19 on China’s Tigecycline market
• – Sales value of China’s Tigecycline 2016-2020
• – Competitive landscape of China’s Tigecycline market
• – Prices of Tigecycline in China
• – Prices of Tigecycline in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Tigecycline market
• – Prospect of China’s Tigecycline market from 2021 to 2025

The post Investigation Report on China’s Tigecycline Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Linezolid in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Linezolid in the Chinese market fell to CNY695 million in 2020, a year-on-year decrease of 14.89%. However, the CAGR of Linezolid sales value in the Chinese market from 2016 to 2020 is still 14.45%.

CRI expects that with the relief of COVID-19, the sales value of Linezolid in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Linezolid has high antibacterial activity against Staphylococcus, Streptococcus pneumoniae, and Enterococcus bacteria, and has no cross-resistance with other antibacterial drugs. It is currently the first choice for the treatment of severe infections such as septic shock. These advantages make sales value and sales volume have room to rise.

Topics Covered:

• -The impact of COVID-19 on China’s Linezolid market
• – Sales value of China’s Linezolid 2016-2020
• – Competitive landscape of China’s Linezolid market
• – Prices of Linezolid in China
• – Prices of Linezolid in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Linezolid market
• – Prospect of China’s Linezolid market from 2021 to 2025

The post Investigation Report on China’s Linezolid Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Nicergoline in the Chinese market has increased year by year from 2016 to 2020. Among them, the growth in 2019 was the most obvious. The sales value of Nicergoline increased from CNY138 million in 2018 to CNY190 million in 2019, with an annual growth rate of 37.57%. In 2020, the sales value of Nicergoline in the Chinese market is CNY237 million, and the CAGR from 2016 to 2020 is 16.6%.

CRI expects that with the increase in the number of patients with Alzheimer’s disease, the sales value of Nicergoline in the Chinese market will continue to grow from 2021 to 2025. By 2020, the incidence of Alzheimer’s disease in the elderly over 65 years old in China was 4%-6%, and the aging degree in China will continue to increase in the future, which will cause the number of patients with Alzheimer’s disease to continue to increase. Therefore, sales volume and sales value in Nicergoline will also continue to increase.

Topics Covered:

• -The impact of COVID-19 on China’s Nicergoline market
• – Sales value of China’s Nicergoline 2016-2020
• – Competitive landscape of China’s Nicergoline market
• – Prices of Nicergoline in China
• – Prices of Nicergoline in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Nicergoline market
• – Prospect of China’s Nicergoline market from 2021 to 2025

The post Investigation Report on China’s Nicergoline Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Atorvastatin in the Chinese market increased from 2016 to 2018. In 2019, due to being included in the Chinese government’s “4+7” policy for drug centralized procurement, the price of the drug fell sharply, resulting in a year-on-year decrease of 18.33% in its sales value. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Atorvastatin in the Chinese market in 2020 dropped to CNY825 million, and the CAGR is about -20.30% from 2016 to 2020.

CRI expects that with the effective relief of COVID-19, the sales value of Atorvastatin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, the seventh census showed that as of the end of 2020, the total population of China was 1,411.78 million, and the population of 60 years and over was 264.02 million, accounting for 18.70% of the total population. It is expected that the elderly population in China will show an increasing trend. The proportion of the elderly population will continue to rise, and the incidence of cardiovascular diseases will continue to rise accordingly. In addition, as the pace of life of Chinese residents accelerates, unhealthy lifestyles increase the risk of blood lipid diseases and expand the market for Atorvastatin. Therefore, CRI predicts that sales value of Atorvastatin in the Chinese market will continue to grow from 2021 to 2025.

The post Investigation Report on China’s Atorvastatin Market 2021-2025 first appeared on CRI Report.

Currently vaccination is one of the most effective approaches to prevent the spread of infectious diseases as well as one of the most cost-effective health intervention measures. Vaccination is helpful to trim down large amount of treatment expense.

The research object of the report is human vaccine apart from animal vaccine. Five pharmaceutical giants, MSD, Sanofi, Glaxo SmithKline, Pfizer and Novartis, take up significant share of the global market, with sales volume of over 80% globally. Yet in terms of vaccine output, these five giants totally produce less than 20% of the global output, meaning most of the vaccines are produced by manufacturers in the developing world.

There are more than 30 vaccine manufacturing companies in China so far. They are capable of producing over 40 varieties of vaccines to prevent more than 20 infectious diseases. Compared with the international market, vaccine manufacturing companies in China have a larger total number yet a smaller individual scale.

In China, it is used to classifying vaccines into two catalogues: Vaccine I and Vaccine II. Vaccine I refers to those free vaccines provided by the government for the public, including vaccines against major epidemic diseases such as hepatitis B, epidemic meningitis and tetanus. Vaccines in this category are all priced by the government and purchased through bidding. Vaccine II mainly covers vaccines paid by citizens themselves. For Vaccine II, pricing falls into the hand of companies, thus offering a higher profit margin and yet forming a more fiercely competitive market. Some of the commonly used vaccines in the Vaccine II catalogue include Pneumonia Vaccine, Varicella Vaccine, Type B Haemophilus Influenzae Conjugate Vaccine, Influenza Vaccine and Rabies Vaccine. In China, Vaccine I market is dominated by state-owned enterprises. Foreign and private enterprises gain certain advantages in the Vaccine II market.

In 2015, vaccine market size in China had a value of about CNY 21 billion. During the corresponding period, however, the whole pharmaceutical market in China reached a scale of over CNY 2,000 billion. Sales of vaccine industry took up only about 1% of the whole pharmaceutical industry, much lower than the average 3% of the global market. Therefore, China’s vaccine market still has much room for growth. China is a country with the largest population in the world. Every year newly born babies exceed 10 million yet meanwhile aging population is witnessing a trend of rise. As the economy advances, movement of population in China is frequent, which objectively adds to the wider and faster spread of diseases globally. Outbreaks of new epidemic diseases (such as Avian Influenza, Type A H1N1 Influenza) are more frequent.

Thanks to the technology accumulation over the years, some of China’s private enterprises have gained significant breakthroughs in both the technological field and the market of Vaccine II. However, as the majority of them produce their products through copy and imitation, they are in lack of strength in core technology, manufacturing technique, innovation and competence.

In China, as some problems still remain in the supervision and regulation in human vaccine industry, related accidents pop up constantly. This makes some Chinese residents tend to choose imported vaccines. The huge potential of China’s human vaccine industry attracts international giants in vaccine industry to speed up their entry to Chinese market. In 2009 Novartis offered to purchase 85% shares of Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. at USD 125 million. Such a bid was approved in March 2011. In June 2011, Glaxo SmithKline bought 51% shares of Neptunus Interlong held by Neptunus Pharmaceutical at GBP 24 million and set up a joint-venture subsidiary. In September 2011, Glaxo SmithKline signed with three new partners which were Sinopharm Group Co., Ltd., Shanghai Zuellig Pharmaceutical Co., Ltd. and Beijing Keyuan Xinhai Pharmaceutical Co., Ltd. The three distributors were respectively responsible for the distribution business in Northern, Central and Southern China. Through their cold chain logistics systems around the nation, they can provide services for clients in different parts of China.

It is estimated that China’s vaccine market will still grow at a fast speed in the next few years. However as market competition is getting more intensified, some of the incompetent companies will end up in bankruptcy or be acquired and restructured. Market concentration rate will constantly go up.

Currently as vaccination rate in China is relatively low, growth in the industry in the future will be large. As China’s economy develops further, residents’ health awareness and paying capacity will continue to be improved, which will offer greater opportunities and market for the vaccine industry.

Through this report, readers can acquire the following information or even more:

-Status of China Vaccine Industry

-Government Policy of China Vaccine Industry

-Competition Status of China Vaccine Market

-Segmentation of China Vaccine Market

-Major Vaccine Manufacturers in China

-Development Trend of Vaccine Market

The following enterprises and people are proposed to purchase this report:

-Vaccine Manufacturers

-Medical and Anti-epidemic Institutions

-Research Institutions/Investors Concerned about Vaccine Industry

Table of Contents

1 Basic Concept of Human Vaccine

1.1 Definition

1.2 Development Course of Vaccines

1.3 Classification of Vaccines

1.4 Necessity of Vaccination

2 Analysis on the Global Human Vaccine Market, 2011-2015

2.1 Scale and Structure of Global Vaccine Market

2.1.1 Scale of Global Vaccine Market

2.1.2 People Appropriate for Vaccination

2.1.3 Structure of Global Vaccine Market

2.2 Vaccines for Children

2.2.1 Major Varieties

2.2.2 Market Scale of Vaccines for Children

2.3 Adult Vaccines

2.3.1 Major Varieties

2.3.2 Market Scale of Adult Vaccines

3 Development Environment of China Human Vaccine Industry, 2011-2016

3.1 Economic Environment

3.2 Policy Environment

3.2.1 China’s Immunization Program History

3.2.2 Procedure of Immunization Program

3.3 Relevant Legislation and Criterion of China Vaccine Industry

3.3.1 Research and Registration Stage

3.3.2 Production Stage

3.2.3 Circulation Stage

3.3.4 Supporting Policies of Chinese Government to Vaccine Industry

3.5 Analysis on Problems in China Human Vaccine Industry

4 Analysis on the China Human Vaccine Market, 2011-2015

4.1 Classification of Chinese Vaccines

4.2 Scale of China Vaccine Market

4.2.1 Overview

4.2.2 Structure of China Vaccine Market

4.3 Classification of Chinese Vaccines According to Government Regulation Degrees

4.3.1 Vaccine I Market

4.3.2 Vaccine II Market

4.4 Market Analysis on Major Vaccines in China

4.4.1 Bacillus Chalmette-Guerin

4.4.2 Poliomyelitis Vaccine

4.4.3 Measles-Mumps-Rubella Vaccine

4.4.4 Diphtheria and Tetanus (DTP or DTaP) Vaccine

4.4.5 Encephalitis Vaccine

4.4.6 Meningococcus Vaccine

4.4.7 Human Rabies Vaccine

4.4.8 Type B Haemophilus Influenzae Conjugate Vaccine

4.4.9 Influenza Vaccine

4.4.10 Varicella Vaccine

4.4.11 Hepatitis A Vaccine

4.4.12 Pneumococcus Vaccine

4.4.13 Hepatitis B Vaccine

5 China’s Major Vaccine Manufacturers, 2011-2015

5.1 China National Biotec Group

5.1.1 Overview

5.1.2 Beijing Tiantan Biological Products Co., Ltd.

5.1.3 Subordinate Institutions of Biological Products of China National Biotec Group

5.2 Hualan Biological Engineering Co., Ltd.

5.3 Yunnan Walvax Biotechnology Co., Ltd.

5.4 Dalian Hissen Biological Pharmaceutical Co., Ltd.

5.5 Changchun High-Tech Industry Co., Ltd.

5.6 Shenzhen Kangtai Biological Products Co., Ltd.

5.7 Neptunus Interlong Bio-Technique Co., Ltd.

5.8 Liaoning Chengda Biotechnology Co., Ltd.

5.9 ChongQing ZhiFei Biological Products Co., Ltd.

6 Prospect of China Vaccine Industry, 2016-2020

6.1 Prediction on Supply and Demand

6.1.1 Prediction on Production

6.1.2 Prediction on Market Scale

6.2 Prediction on Development Trend

6.2.1 Technology Trend

6.2.2 Market Trend

6.2.3 Competition Trend

Selected Charts

Chart Introduction on Basic Ingredients of Vaccine

Chart Classification of Human Vaccines

Chart Comparison Between Traditional and New Vaccines

Chart Scale of the Global Vaccine Market, 2005-2015

Chart Introduction on Global Major Vaccines

Chart Major Varieties of Global Pneumonia Vaccine

Chart Major Hepatitis Vaccine in Global Market

Chart World’s Major Infectious Diseases Since the 21st Century

Chart Market Scale of China Vaccine Industry, 2011-2015

Chart Lot Release Volume of BCG Vaccine in China, 2011-2015

Chart Market Scale of China’s MMR Vaccine, 2011-2015

Chart Lot Release Volume of Human Rabies Vaccine in China, 2011-2015

Chart Lot Release Volume of Influenza Vaccine in China, 2011-2015

Chart Prediction on Market Scale of China Vaccine Industry, 2016-2020

Chart Immunization Program Procedure for Chinese Children

Chart Circulation of China’s Vaccines

Chart Prediction on Scale of China Vaccine Market, 2016-2020

The post Research Report on China Human Vaccine Industry, 2011-2020 first appeared on CRI Report.